Publication | Open Access
Moderate‐to‐severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real‐world experience
55
Citations
23
References
2022
Year
Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era.
| Year | Citations | |
|---|---|---|
Page 1
Page 1